Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Rhea-AI Summary

VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for February 14, 2025, at 8:00 AM ET. The event, titled 'Casting a New Light on Sepsis Management,' will feature presentations from Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer.

Dr. Retter will discuss Nu.Q® NETs H3.1, a novel biomarker for early mortality and organ dysfunction in sepsis, which also serves as an independent predictor for renal replacement therapy needs. Recent large-scale study results suggest potential clinical applications in risk stratification and early intervention for critically ill sepsis patients.

Mr. Forterre will provide updates on Volition's commercialization strategies through licensing and sales channels. The event will conclude with a live Q&A session.

News Market Reaction

+0.02%

1 alert

+0.02% News Effect

On the day this news was published, VNRX gained 0.02%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here.

Dr. Retter will focus on Nu.Q® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.

Mr. Forterre will provide an update on Volition's progress to commercialization through both licensing and direct and indirect sales.

A live question and answer session will follow the formal presentations.

About Dr. Andrew Retter

Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care, ECMO & Thrombois and also the Clinical Lead for Critical Care at one of the UK's largest hospitals in London, where he has worked as a  Consultant since 2014. He is also the Chief Medical Officer at Volition, a medical technology company that specializes in developing innovative diagnostic tools for cancer, sepsis and in particular immunothrombosis. Dr Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals.

About Gael Forterre

Gael Forterre is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q^® platform. Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Pathify. He is currently the non-executive chairman of Vahau.

Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568

View original content:https://www.prnewswire.com/news-releases/volition-to-host-virtual-investor-event-on-nuq-nets-casting-a-new-light-on-sepsis-management-on-february-14-2025-302368817.html

SOURCE VolitionRx Limited

FAQ

When is VolitionRx (VNRX) hosting its virtual investor event on Nu.Q® NETs?

VolitionRx is hosting the virtual investor event on Friday, February 14, 2025, at 8:00 AM ET.

What will be discussed at VNRX's February 2025 investor event?

The event will focus on Nu.Q® NETs H3.1, a biomarker for sepsis management, and provide updates on Volition's commercialization progress through licensing and sales channels.

What are the key findings about Nu.Q® NETs H3.1 biomarker mentioned in VNRX's announcement?

Nu.Q® NETs H3.1 is identified as a novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor for renal replacement therapy needs, with potential applications in risk stratification and early intervention.

Who are the key speakers at VNRX's February 14 investor event?

The key speakers are Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer of Volition.

What commercial updates will be presented at the VNRX February 2025 event?

Gael Forterre will provide updates on Volition's progress toward commercialization through both licensing and direct and indirect sales channels.